You are here

OASIS PHARMACEUTICALS, LLC

Company Information
Address
64 FIFER LN
LEXINGTON, MA 02420-1226
United States



Information

UEI: F2ZWBFV5NZ86

# of Employees: 5


Ownership Information

HUBZone Owned: No

Socially and Economically Disadvantaged: No

Woman Owned: No



Award Charts




Award Listing

  1. Lipid Receptor GPR31 as a Target for Anti-Thrombotic and Stroke Therapy

    Amount: $999,799.00

    Despite prevalent use of anti-platelet and anti-lipid therapies, stroke remains the third major cause of death and is the leading cause of adult disability in the US with an estimated cost in the rang ...

    STTRPhase II2023Department of Health and Human Services National Institutes of Health
  2. Development of liver homing PAR2 pepducins for the treatment of HepatocellularCarcinoma

    Amount: $392,485.00

    Hepatocellular carcinoma (HCC) has become the second leading cause of cancer-related death in the world, with a 72% mortality rate in the US. The rise in incidence of HCC is due to a steady increase i ...

    STTRPhase I2022Department of Health and Human Services National Institutes of Health
  3. Lipid Receptor GPR31 as a Target for Anti-Thrombotic and Stroke Therapy

    Amount: $361,774.00

    Despite prevalent use of anti-platelet and anti-lipid therapies, stroke remains the third major cause of death and is the leading cause of adult disability in the US with an estimated cost in the rang ...

    STTRPhase I2021Department of Health and Human Services National Institutes of Health
  4. PAR2 Pepducins as a Novel Treatment of Idiopathic Pulmonary Fibrosis

    Amount: $1,491,074.00

    Idiopathic pulmonary fibrosis (IPF), the most common of the interstitial lung diseases, occurs in about 128,000 people, with 48,000 new cases diagnosed annually in the US. The typical clinical course ...

    STTRPhase II2019Department of Health and Human Services National Institutes of Health
  5. PAR2 Pepducins as a Novel Treatment of Idiopathic Pulmonary Fibrosis

    Amount: $225,769.00

    Idiopathic pulmonary fibrosisIPFthe most common of the interstitial lung diseasesoccurs in aboutpeoplewithnew cases diagnosed annually in the USThe typical clinical course is a progressive fibrotic di ...

    STTRPhase I2018Department of Health and Human Services National Institutes of Health
  6. Development of PAR Pepducins as a Novel Antithrombotic Treatment

    Amount: $366,484.00

    Coronary artery disease remains the leading cause of death in the United States Platelets play an important role in the pathogenesis of acute coronary syndrome ACS as platelet activation aggregat ...

    STTRPhase I2017Department of Health and Human Services National Institutes of Health
  7. Development of PAR2 Pepducins as a Novel NASH Treatment

    Amount: $3,165,348.00

    Non alcoholic steatohepatitisNASHis characterized by fatty changes in the liver with inflammation and hepatocellular injury that in advanced stages leads to fibrosiscirrhosis and high mortality ratesN ...

    SBIRPhase II2017Department of Health and Human Services National Institutes of Health
  8. Development of PAR Pepducins for the Treatment of Atopic Dermatitis

    Amount: $1,500,000.00

    DESCRIPTION provided by applicant Atopic dermatitis AD or severe eczema is a very common life long skin disease with of adults in the US requiring systemic therapy Clinical manifestations of ...

    STTRPhase II2016Department of Health and Human Services National Institutes of Health
  9. Development of PAR2 Pepducins for the Treatment of Atopic Dermatitis

    Amount: $225,000.00

    DESCRIPTION provided by applicant Atopic dermatitis AD or severe eczema is a very common life long skin disease with of adults in the US requiring systemic therapy Clinical manifestations of ...

    STTRPhase I2015Department of Health and Human Services National Institutes of Health
  10. Development of PAR2 Inhibitors for the Treatment of Nonalcoholic steatohepatitis

    Amount: $1,742,618.00

    DESCRIPTION provided by applicant Non alcoholic steatohepatitis NASH is characterized by fatty changes in the liver with inflammation and hepatocellular injury that in advanced stages leads to fi ...

    STTRPhase II2014Department of Health and Human Services National Institutes of Health
US Flag An Official Website of the United States Government